Clinical Trial Update: A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients [Phase 2]

View source ↗

Summary

This Phase 2 trial assessed the effectiveness, safety, and pharmacokinetics of TMC435 with peginterferon alfa-2a and ribavirin in chronic hepatitis C; results w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Peginterferon alfa-2a (peginterferon alfa-2a)
• Ribavirin (ribavirin)
• TMC435

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2014-04-17